The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comprehensive genetic characterization of 12 AML cell lines using a novel AML targeted sequencing strategy.
Andrew R. Carson
No relevant relationships to disclose
Bradley A. Patay
Employment or Leadership Position - Genection
Consultant or Advisory Role - Genection
Stock Ownership - Genection
Suzanne M. Graham
No relevant relationships to disclose
Ross Cubbon
No relevant relationships to disclose
Jeffrey E. Miller
Employment or Leadership Position - Genection; Invivoscribe; LabPMM
Consultant or Advisory Role - Genection; Invivoscribe; LabPMM
Stock Ownership - Invivoscribe